We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Growing Need for IT in Life Sciences

By Biotechdaily staff writers
Posted on 21 Dec 2005
The growth of data and the need for regulatory compliance are driving expenditures for information technology (IT) in the life sciences. More...
Total IT world-wide spending is forecast to reach U.S.$49.30 billion in 2011, compared to $17.10 billion in 2004, according to a new report from Frost & Sullivan (Palo Alto, CA, USA).

Surging volumes of data in the life sciences industry have created a challenge for scientists who must collect and analyze them. In spite of the fact that life science companies have large repositories of paper-based data, there is a high market potential for IT vendors in digitizing, storing, and managing this data throughout its life cycle. Companies are also realizing the importance of combining data from various locations and storing it in a central warehouse.

"The life science industry is now in a period of transition, as it seeks to use IT to resolve the process inefficiencies that cause a lot of dollars to be wasted across the spectrum, from R&D to post-marketing,” noted Raghavendra Chitta, an industry analyst with Frost & Sullivan.

IT is proving to be a key tool in helping companies communicate regulatory requirements across business areas. Recent market withdrawals of drugs have created an increased focus on pharmacovigilance and related regulatory compliance. While big pharmaceutical companies hold potential for IT vendors because of their more mature, predictable, and large IT budgets, they are more complex customers. Drug recalls and pricing pressures have resulted in the rationalization of operational costs. The larger drug companies have already replaced legacy systems, leaving little chance for increased IT spending.

As a result, the entire selling structure in the life sciences is moving towards value-based selling and tools in the industry that generate value. IT companies, therefore, have to develop return-on-investment (ROI) models and provide proof for these values. At the same time, developing new tools that are capable, interoperative, and can run on existing infrastructure--offering customizing, consulting services, and easy integration--will also be critical to success.






Related Links:
Frost & Sullivan

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.